title: [Initial antithrombotic therapy for pulmonary embolism].
abstract: The initial therapy for patients with pulmonary embolism who are haemodynamically stable relies on antithrombotic treatment. The aim of anticoagulant treatment is to prevent any thrombus extension or recurrence, with revascularization dependent on the fibrinolytic system. Current treatment is biphasic, with parenteral heparin or derivatives (low molecular weight heparins and fondaparinux) followed by oral vitamin K antagonists. Although these treatments are efficient, they suffer from some limitations including parenteral administration and the need for surveillance and monitoring. Use of low molecular weight heparins or fondaparinux is recommended in French guidelines, but unfractionated heparin still has an important role in some specific situations such as severe renal insufficiency, around the time of surgery and where there is a high risk of bleeding. The next generation of anticoagulants will soon be licensed for treatment in pulmonary embolism and may well replace heparin and/or vitamin K antagonists for the majority of patients, although "older" treatments will always be requested in some specific situations.
authors.affiliation: Groupe de recherche sur la thrombose, université de Saint-Étienne, Saint-Étienne, France. laurent.bertoletti@gmail.com
authors.forename: L
authors.initials: L
authors.lastname: Bertoletti
authors.forename: P
authors.initials: P
authors.lastname: Mismetti
mesh_terms: D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D011655:Pulmonary Embolism / Q000188:drug therapy*
chemical_list: D005343:Fibrinolytic Agents; D006493:Heparin